Department of Nephrology, Rambam Health Care Campus, Haifa, Israel.
Department of Nephrology, Rambam Health Care Campus, Haifa, Israel; Department of Nephrology, Mayanei HaYeshua Medical Center, Bnei Brak, Israel.
Semin Nephrol. 2017 Nov;37(6):490-507. doi: 10.1016/j.semnephrol.2017.07.002.
Common DNA sequence variants rarely have a high-risk association with a common disease. When such associations do occur, evolutionary forces must be sought, such as in the association of apolipoprotein L1 (APOL1) gene risk variants with nondiabetic kidney diseases in populations of African ancestry. The variants originated in West Africa and provided pathogenic resistance in the heterozygous state that led to high allele frequencies owing to an adaptive evolutionary selective sweep. However, the homozygous state is disadvantageous and is associated with a markedly increased risk of a spectrum of kidney diseases encompassing hypertension-attributed kidney disease, focal segmental glomerulosclerosis, human immunodeficiency virus nephropathy, sickle cell nephropathy, and progressive lupus nephritis. This scientific success story emerged with the help of the tools developed over the past 2 decades in human genome sequencing and population genomic databases. In this introductory article to a timely issue dedicated to illuminating progress in this area, we describe this unique population genetics and evolutionary medicine detective story. We emphasize the paradox of the inheritance mode, the missing heritability, and unresolved associations, including cardiovascular risk and diabetic nephropathy. We also highlight how genetic epidemiology elucidates mechanisms and how the principles of evolution can be used to unravel conserved pathways affected by APOL1 that may lead to novel therapies. The APOL1 gene provides a compelling example of a common variant association with common forms of nondiabetic kidney disease occurring in a continental population isolate with subsequent global admixture. Scientific collaboration using multiple experimental model systems and approaches should further clarify pathomechanisms further, leading to novel therapies.
常见的 DNA 序列变异很少与常见疾病有高风险关联。当这种关联确实发生时,就必须寻找进化力量,例如载脂蛋白 L1(APOL1)基因风险变异与非糖尿病肾病在非洲裔人群中的关联。这些变体起源于西非,并在杂合状态下提供了致病性抗性,导致高等位基因频率,这是由于适应性进化选择清扫。然而,纯合状态是不利的,并与一系列肾脏疾病的风险显著增加有关,包括高血压相关的肾脏疾病、局灶节段性肾小球硬化症、人类免疫缺陷病毒肾病、镰状细胞肾病和进行性狼疮性肾炎。这个科学成功故事是在过去 20 年中人类基因组测序和人口基因组数据库发展的帮助下出现的。在本期及时出版的专题文章中,我们描述了这个独特的群体遗传学和进化医学侦探故事。我们强调了遗传模式的悖论、缺失的遗传力和未解决的关联,包括心血管风险和糖尿病肾病。我们还强调了遗传流行病学如何阐明机制,以及进化原则如何用于揭示受 APOL1 影响的保守途径,这可能导致新的治疗方法。APOL1 基因提供了一个引人注目的例子,说明了常见的变异与非糖尿病肾病的常见形式在大陆人群隔离后发生的关联,随后发生了全球混合。使用多种实验模型系统和方法的科学合作应该进一步阐明发病机制,从而导致新的治疗方法。